This phase II trial studies how well everolimus with or without trastuzumab works in treating
patients with breast cancer that has not responded to hormone therapy and has spread from
where it started to other places in the body. Everolimus may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
trastuzumab, may interfere with the ability of tumor cells to grow and spread. Giving
everolimus and adding trastuzumab at the time of disease progression may be an effective
treatment for breast cancer.